The Chinese biotech said US regulators have cleared it to start trials of the therapy for patients with B-cell lymphoma.

The firm reported $11.4 million in net revenue from Zevaskyn for the three months ended June 30, missing analysts' expectations of roughly $12.3 million.

PMC's new president and CEO said the organization is expanding beyond oncology, engaging with Capitol Hill, and challenging a controversial research grant rule.

NEW YORK – Akeso Bio has launched a Phase II study of a bispecific antibody-drug conjugate in combination with its bispecific antibody ivonescimab for advanced breast cancer. The Zhongshan, ...

The investigator-initiated trial comes after Elicio said a Phase II trial of ELI-002 7P in adjuvant pancreatic cancer did not meet its primary endpoint.

The firm disclosed the update on the gene therapy, which it acquired in its 2021 purchase of Prevail Therapeutics, in its Q2 ...

US regulators are already reviewing data from a later-line trial, but Taiho now says it could seek a first-line indication for the EGFR inhibitor.

The deal centers on Actio's small molecule for KCNT1-related epilepsy. Meanwhile, Actio will spin out a separate company with its other assets.

The biotech will use the funds to advance its pipeline of epigenetic medicines, starting with its candidate EPI-321 for a type of muscular dystrophy.

Revenue from the CAR T-cell therapy for later-line acute lymphoblastic leukemia more than doubled year-over-year.

The firm reported median overall survival of 26 months in patients with recurrent, high-grade, IDH1-mutant gliomas in a Phase II study.